Tevogen Bio Holdings Inc. announced that it completed a series of operational milestones in 2025, including enhancements to its ExacTcell™ platform that increased laboratory yields of target‑specific cytotoxic T lymphocytes (CTLs) per product. The improvements are designed to enable efficient clinical supply and support future commercial manufacturing across multiple programs using shared infrastructure.
The company also expanded its pipeline, completing target identification for five additional HLA restrictions for its SARS‑CoV‑2‑specific CTL product and advancing preclinical activities for new CTL therapies in virology and oncology. The expanded HLA coverage broadens patient coverage and opens additional therapeutic indications for the platform.
In addition, Tevogen established in‑house GMP cell‑therapy manufacturing capabilities, laying the foundation for scalable production of its cell‑based products. A letter of intent to lease a 17,428‑square‑foot facility in New Jersey, formerly occupied by Pfizer and Cordis, supports the move toward commercial manufacturing.
CEO Ryan Saadi emphasized that 2025 was a defining execution year, noting that the company has built a scalable CTL platform, expanded into multiple high‑value indications, and laid the manufacturing foundation required to translate its science into clinical and commercial outcomes. The company also highlighted plans to share updates on AI capabilities, financial strategy, and commercialization at the J.P. Morgan Healthcare Conference.
The announcement signals a transition from early‑stage proof‑of‑concept to a manufacturable, commercially viable platform, a critical milestone for a pre‑revenue biotech seeking to secure future funding and move toward product launch. The company’s progress also positions it to address unmet needs in infectious diseases, cancers, and neurological disorders, while its AI division, Tevogen.AI, accelerates peptide target identification and prioritization.
The company also received a Nasdaq notice regarding its minimum bid price requirement, with a compliance deadline of March 23, 2026. The notice underscores the importance of maintaining liquidity and financial stability as Tevogen advances toward commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.